NCT04937413View on ClinicalTrials.gov

The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

October 8, 2021

Primary Completion Date

September 13, 2023

Study Completion Date

October 12, 2023

Conditions

Malignant GliomaGlioblastoma

Interventions

DRUG

Evolocumab

Evolocumab subcutaneous injection

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University

All Listed Sponsors

lead

Duke University

OTHER